Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism/kallmann syndrome and effects of different modalities of hormonal treatment: A single-center study of 281 patients

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages

  Trabado, Séverine ^a,b,d   Maione, Luigi ^a,b,d   Bry Gauillard, Hélène ^b   Affres, Hélène ^b   Salenave, Sylvie ^a,b   Sarfati, Julie ^a,b   Bouvattier, Claire ^a,b   Delemer, Brigitte ^c   Chanson, Philippe ^a,b,d   Bouc, Yves Le ^e   Brailly Tabard, Sylvie ^a,b,d   Young, Jacques ^a,b,d  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c SERVICE DE DERMATOLOGIE   (France)

^d INSERM   (France)

^e ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CHORIONIC GONADOTROPIN; DRUG THERAPY, COMBINATION; FOLLICLE STIMULATING HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INSULIN; KALLMANN SYNDROME; LUTEINIZING HORMONE; MALE; PROTEINS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84893746947     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2288     Document Type: Article

References (36)

1. Ferlin A, Foresta C. Insulin-like factor 3: a novel circulating hormone of testicular origin in humans. AnnNY Acad Sci. 2005;1041: 497-505.
2. Foresta C, Zuccarello D, Garolla A, Ferlin A. Role of hormones, genes, and environment in human cryptorchidism. Endocr Rev. 2008;29:560-580.
3. Ivell R, Anand-Ivell R. Biology of insulin-like factor 3 in human reproduction. Hum Reprod Update. 2009;15:463-476.
4. Bay K, Main KM, Toppari J, Skakkebæk NE. Testicular descent: INSL3, testosterone, genes and the intrauterine milieu. Nat Rev Urol. 2011;8:187-196.
5. Nef S, Parada LF. Cryptorchidism in mice mutant for Insl3. Nat Genet. 1999;22:295-299.
6. Zimmermann S, Steding G, Emmen JM, et al. Targeted disruption of the Insl3 gene causes bilateral cryptorchidism. Mol Endocrinol. 1999;13:681-691.
7. Overbeek PA, Gorlov IP, Sutherland RW, et al. A transgenic insertion causing cryptorchidism in mice. Genesis. 2001;30:26-35.
8. Bay K, Cohen AS, Jørgensen FS, et al. Insulin-like factor 3 levels in second-Trimester amniotic fluid. J Clin Endocrinol Metab. 2008;93: 4048-4051.
9. Bay K, Virtanen HE, Hartung S, et al, and the Nordic Cryptorchidism Study Group. Insulin-like factor 3 levels in cord blood and serum from children: effects of age, postnatal hypothalamic-pituitary-gonadal axis activation, and cryptorchidism. J Clin Endocrinol Metab. 2007;92:4020-4027.
10. Ferlin A, Garolla A, Rigon F, Rasi Caldogno L, Lenzi A, Foresta C. Changes in serum insulin-like factor 3 during normal male puberty. J Clin Endocrinol Metab. 2006;91:3426-3431.
11. Bay K, Hartung S, Ivell R, et al. Insulin-like factor 3 serum levels in 135 normal men and 85 men with testicular disorders: relationship to the luteinizing hormone-Testosterone axis. J Clin Endocrinol Metab. 2005;90:3410-3418.
12. Foresta C, Bettella A, Vinanzi C, et al. A novel circulating hormone of testis origin in humans. J Clin Endocrinol Metab. 2004;89:5952-5958.
13. Bay K, Matthiesson KL, McLachlan RI, Andersson AM. The effects of gonadotropin suppression and selective replacement on insulinlike factor 3 secretion in normal adult men. J Clin Endocrinol Metab. 2006;91:1108-1111.
14. Young J. Approach to the male patient with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2012;97:707-718.
15. Bouvattier C, Maione L, Bouligand J, Dodé C, Guiochon-Mantel A, Young J. Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism. Nat Rev Endocrinol. 2012;8:172-182.
16. Young J, Rey R, Couzinet B, Chanson P, Josso N, Schaison G. Antimüllerian hormone in patients with hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 1999;84:2696-2699.
17. Young J, Couzinet B, Chanson P, Brailly S, Loumaye E, Schaison G. Effects of human recombinant luteinizing hormone and folliclestimulating hormone in patients with acquired hypogonadotropic hypogonadism: study of Sertoli and Leydig cell secretions and interactions. J Clin Endocrinol Metab. 2000;85:3239-3244.
18. Young J, Chanson P, Salenave S, et al. Testicular anti-mullerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2005;90:724-728.
19. Maione L, Benadjaoud S, Eloit C, et al. Computed tomography of the anterior skull base in Kallmann syndrome reveals specific ethmoid bone abnormalities associated with olfactory bulb defects. J Clin Endocrinol Metab. 2013;98:E537-E546.
20. Bouligand J, Ghervan C, Tello JA, et al. Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation. N Engl J Med. 2009;360:2742-2748.
21. Young J, Bouligand J, Francou B, et al. TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. J Clin Endocrinol Metab. 2010;95:2287-2295.
22. Foresta C, Di Mambro A, Pagano C, Garolla A, Vettor R, Ferlin A. Insulin-like factor 3 as a marker of testicular function in obese men. Clin Endocrinol (Oxf). 2009;71:722-726.
23. Anand-Ivell R, Wohlgemuth J, Haren MT, et al. Peripheral INSL3 concentrations decline with age in a large population of Australian men. Int J Androl. 2006;29:618-626.
24. Amory JK, Page ST, Anawalt BD, Coviello AD, Matsumoto AM, Bremner WJ. Elevated end-of-Treatment serum INSL3 is associated with failure to completely suppress spermatogenesis in men receiving male hormonal contraception. J Androl. 2007;28:548-554.
25. Roth MY, Lin K, Bay K, et al. Serum insulin-like factor 3 is highly correlated with intratesticular testosterone in normal men with acute, experimental gonadotropin deficiency stimulated with lowdosehumanchorionic gonadotropin: a randomized, controlled trial. Fertil Steril. 2013;99:132-139.
26. Salenave S, Chanson P, Bry H, et al. Kallmann's syndrome: a comparison of the reproductive phenotypes in men carrying KAL1 and FGFR1/KAL2 mutations. J Clin Endocrinol Metab. 2008;93:758-763.
27. Sarfati J, Guiochon-Mantel A, Rondard P, et al. A comparative phenotypic study of Kallmann syndrome patients carrying monoallelic and biallelic mutations in the prokineticin 2 or prokineticin receptor 2 genes. J Clin Endocrinol Metab. 2010;95:659-669.
28. Quinton R, Cheow HK, Tymms DJ, Bouloux PM, Wu FC, Jacobs HS. Kallmann's syndrome: is it always for life? Clin Endocrinol (Oxf). 1999;50:481-485.
29. Raivio T, Falardeau J, Dwyer A, et al. Reversal of idiopathic hypogonadotropic hypogonadism.NEngl JMed. 2007;357:863-873.
30. Bay K, Andersson AM. Human testicular insulin-like factor 3: in relation to development, reproductive hormones and andrological disorders. Int J Androl. 2011;34:97-109.
31. Ivell R, Wade JD, Anand-Ivell R. INSL3 as a biomarker of leydig cell functionality. Biol Reprod. 2013;88(6):147.
32. Wartofsky L, Handelsman DJ. Standardization of hormonal assays for the 21st century. J Clin Endocrinol Metab. 2010;95:5141-5143.
33. Hutson JM, Southwell BR, Li R, et al. The regulation of testicular descent and the effects of cryptorchidism. Endocr Rev. 2013;34(5): 725-752.
34. Pitteloud N, Hayes FJ, Boepple PA, et al. The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002; 87:152-160.
35. Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF Jr. Predictors of outcome of long-Term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002;87:4128-4136.
36. Sykiotis GP, Hoang XH, Avbelj M, et al. Congenital idiopathic hypogonadotropic hypogonadism: evidence of defects in the hypothalamus, pituitary, and testes. J Clin Endocrinol Metab. 2010;95: 3019-3027.